David Bodkin

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney, A.J. Grillo-López, David Bodkin et al. · Journal of Clinical Oncology · 1997 · 638 citations

Pharmacy, Hematology, Pharmacokinetics +17

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

J. Gutheil, Tanya Campbell, Paul R. Pierce et al. · PubMed · 2000 · 370 citations

Medicine, Pharmacokinetics, Pharmacology +17

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2009 · 226 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

Charles Butts, David Bodkin, Edward L. Middleman et al. · Journal of Clinical Oncology · 2007 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17